Critically examine how PMBJP and PLI schemes together advance both affordable healthcare and Atmanirbharta in India's pharma sector.

Q. Critically examine how PMBJP and PLI schemes together advance both affordable healthcare and Atmanirbharta in India's pharma sector. (15 marks, 250-350 words)

India is the "Pharmacy of the World", supplying ~20% of global generics and 60% of global vaccines [2]. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) and the Production Linked Incentive (PLI) schemes form a dual-track strategy under the Department of Pharmaceuticals — demand-side affordability and supply-side self-reliance — that is substantially, though not fully, successful.

Advancing affordable healthcare (PMBJP) - Scale: Jan Aushadhi Kendras grew from 84 (2014) to over 19,200 (2026), with 20,149 opened till June 2026 [1][5]. - Price relief: generics sold 50–90% cheaper than branded equivalents, saving citizens ₹40,000 crore+ — cutting catastrophic out-of-pocket expenditure and operationalising the Article 21 right to health [1][5]. - Equity: North-East Kendras rose from 1 to 417, narrowing regional access gaps [1].

Advancing Atmanirbharta (PLI & Parks) - PLI Pharmaceuticals (₹15,000 crore, 2021): cumulative investment ₹42,694.89 crore, sales ₹3.43 lakh crore, 1.13 lakh+ jobs [1]. - PLI Bulk Drugs (₹6,940 crore) plus three Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh (₹1,000 crore assistance each) target API/KSM import dependence exposed by COVID-19 supply shocks [3]. - PRIP (₹5,000 crore) shifts the sector from volume-generics toward complex generics, biosimilars and novel devices [2].

Critical assessment - Affordability is volume-limited: JAK medicines remain a small share of the retail market, and the 25,000-Kendra target by March 2027 is still pending [5]. - Quality assurance and supply irregularity at Kendras, plus overlapping CDSCO–NPPA–DoP mandates, weaken consumer confidence. - Import reliance on Chinese KSMs persists despite investment exceeding commitments (₹4,570 crore by March 2025), since cost competitiveness, not capacity alone, drives sourcing [3].

The two schemes are therefore complementary rather than duplicative: PLI secures the manufacturing base that makes PMBJP's low prices sustainable. Strengthening quality testing, expanding Kendras into aspirational districts, and sustaining PRIP-led innovation would convert cost leadership into value leadership — realising both universal health coverage under SDG-3 and a genuinely self-reliant pharmaceutical economy.

(~330 words)

Sources: 1. 12 Years of Transformative Growth in Pharmaceuticals Sector, PIB (2026) — JAK growth 84→19,200+, ₹40,000 cr savings, PLI Pharma investment/sales/jobs, North-East 1→417 2. India's Pharmaceuticals in Global Healthcare, PIB — 20% of global generics, 60% of global vaccines, PRIP ₹5,000 crore outlay 3. Bulk Drug Parks, PIB — three parks (AP, Gujarat, HP), ₹1,000 crore assistance each, API import substitution 4. Schemes for Atmanirbhar Bharat in the Pharmaceutical Sector, PIB — PLI Bulk Drugs outlay and investment exceeding commitments 5. PMBJP — Quality Generic Medicines at Affordable Prices, PIB — 50–90% price discount, 20,149 JAKs till 30.06.2026, 25,000-Kendra target by March 2027